LEXICON PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Net Income (Loss)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$97.82 million for the 12-month period ending 2010-12-31, per its 10-K filed 2013-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2013-03-11
- LEXICON PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2010 was -$97.82M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2010-12-31 | -$97.82M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |